Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558097 | 0.86 | TUBB1 (0.43) | DUTTUBB1KDM4EALDH1A1PKM | |
| SCHEMBL17558158 | 0.82 | TUBB1 (0.41) | DUTPTGDR2TUBB1KDM4EALDH1A1 | |
| SCHEMBL28693496 | 0.81 | ALDH1A1 (0.56) | DUTPTGDR2KDM4EALDH1A1MEN1 | |
| SCHEMBL28580980 | 0.80 | ALDH1A1 (0.57) | DUTPTGDR2KDM4EALDH1A1MEN1 | |
| SCHEMBL9560068 | 0.79 | NR5A1 (0.51) | CYSLTR2CYSLTR1ALDH1A1 | |
| SCHEMBL7263728 | 0.79 | ERN1 (0.37) | BACE1PTGDR2KDM4EALDH1A1CAPN1 | |
| SCHEMBL3365594 | 0.76 | PTGDR2 (0.51) | DUTPTGDR2ALDH1A1MEN1MAPT | |
| SCHEMBL274474 | 0.76 | ALDH1A1 (0.38) | DUTPTGDR2TUBB1KDM4EALDH1A1 | |
| SCHEMBL2151914 | 0.76 | ALDH1A1 (0.45) | KDM4EALDH1A1PKMMEN1MAPT | |
| SCHEMBL17558157 | 0.76 | CNR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188760-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| CN-107072946-B | Lipids and lipid compositions for delivery of active agents | 诺华股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-10125092-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| EP-3188760-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016037053-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LIPA, LPAR1 | BACE1 4522/4885DUT 4063/4885PTGDR2 1424/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | BACE1 4552/4885DUT 4073/4885PTGDR2 1530/4885 |
| US-10125092-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LPAR4, LPAR1 | BACE1 4552/4885DUT 4073/4885PTGDR2 1530/4885 |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LIPA, LPAR1 | BACE1 4522/4885DUT 4063/4885PTGDR2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.